中国近年不同地区医药高科技产业研发效率分析

doi:10.3969/j.issn.2096-045X.2023.01.021

医学教育管理 ›› 2023, Vol. 9 ›› Issue (1): 116-121.doi: 10.3969/j.issn.2096-045X.2023.01.021

中国近年不同地区医药高科技产业研发效率分析

刘扬，郭翔宇*

首都医科大学药学院，北京 100069

收稿日期:2022-03-07 出版日期:2023-02-20 发布日期:2023-03-17
通讯作者: 郭翔宇

Research and development efficiency of pharmaceutical high-tech industry in different regions of China in recent years

Liu Yang, Guo Xiangyu*

Pharmaceutical Science School, Capital Medical University, Beijing 100069,China

Received:2022-03-07 Online:2023-02-20 Published:2023-03-17

摘要/Abstract

摘要： 目的比较我国近年不同地区医药高科技产业的研发效率。方法整理2015-2019年医药高科技产业研发的投入和产出数据，使用数据包络模型对研发效率测度和分析。结果研发效率呈现地域性不均衡的特点；24个地区存在不同程度的规模过剩；25个地区的研发效率有很大提升空间。结论高校、科研机构应加强对研发效率的测度和方法学研究；政府结合测度结果分析制定精准定向的鼓励政策，通过减少投入量、优化研发投入比例或强化产出目标来提高效率。

关键词: 医药高科技产业, 研发效率, 投入, 产出, 数据包络分析

Abstract: Objective To compare research and development (R&D) efficiency of pharmaceutical high-tech industry in different regions of China in recent years. Methods The input and output data of pharmaceutical high-tech industry R&D from 2015 to 2019 were sorted out, and the data envelopment model was used to measure and analyze the R&D efficiency. Results Regional imbalance characteristic is found in R&D efficiency. Twenty-four regions have different degrees of scale excess. Room for improvement exists in R&D efficiency in 25 regions. Conclusion Universities and research institutions should strengthen the measurement and methodology research of R&D efficiency. Based on the analysis of the measurement results, local government will formulate precise and targeted encouragement policies to improve efficiency by reducing the input, optimizing the proportion of R&D input or strengthening the output target.

Key words: pharmaceutical high-tech industry, R&D efficiency, input, output, data envelopment analysis

中图分类号:

R956
G644

刘扬, 郭翔宇. 中国近年不同地区医药高科技产业研发效率分析[J]. 医学教育管理, 2023, 9(1): 116-121.

Liu Yang, Guo Xiangyu. Research and development efficiency of pharmaceutical high-tech industry in different regions of China in recent years[J]. Medical Education Management, 2023, 9(1): 116-121.

参考文献

［1］Ni J Y, Zhao J R, Ung C O L, et al. Obstacles and opportunities in Chinese pharmaceutical innovation［J］. Global Health, 2017, 13(1): 21.
［2］王广平, 石晟怡, 王颖, 等. 审评审批制度改革背景下医药产业组织结构调整路径研究［J］. 中国药事, 2019, 33(1): 1-11.
［3］Qiu L, Chen Z Y, Lu D Y, et al. Public funding and private investment for R&D: a survey in Chinas pharmaceutical industry［J］. Health Res Policy Syst, 2014, 12: 27.
［4］马恒, 饶惠霞. 广东省医药制造业研发资金投入影响的实证分析［J］. 发展改革理论与实践, 2018(6): 24-28.
［5］Qin X H, Du D B. Measuring universities’ R&D performance in China’s provinces: a multistage efficiency and effectiveness perspective［J］. Technol Anal Strateg Manag, 2018, 30(12): 1392-1408.
［6］李小平. 研发效率测度及其影响因素——评《中国与世界主要国家(地区)研发效率: 测度方法、国际比较及影响因素》［J］. 科技进步与对策, 2021, 38(10): 后插1.
［7］Dobrzanski P. The efficiency of spending on R&D in Latin America region［J］. Appl Econ, 2020, 52(46): 5020-5034.
［8］张曦, 郭淑芬. 中国工业技术创新效率的时空特征与动态演进［J］. 统计学报, 2021, 2(1): 61-70.
［9］张慧珍. 福建省科技创新效率研究——基于DEA方法的实证分析［J］. 石家庄铁道大学学报(社会科学版), 2021, 15(1): 22-27.
［10］Hashimoto A, Haneda S. Measuring the change in R&D efficiency of the Japanese pharmaceutical industry［J］. Res Policy, 2008, 37(10): 1829-1836.
［11］吉生保, 周小柯. 中国医药制造业研发效率研究——基于HMB生产率指数的经验证据［J］. 财经论丛, 2010(6): 10-15.
［12］洪进, 李敬飞, 李晓芬. 两阶段创新价值链视角下的我国医药制造业技术创新效率及影响因素分析［J］. 西北工业大学学报(社会科学版), 2013, 33(2): 51-56, 64.
［13］金安琪, 杨光, 李斐琳, 等. 基于DEA的中成药上市企业研发效率评价［J］. 中国现代中药, 2021, 23(4): 719-726.
［14］Thanassoulis E. Introduction to the theory and application of data envelopment analysis: a foundation text with integrated software［M］. New York: Springer, 2001.
［15］Banker R D, Charnes A, Cooper W W. Some models for estimating technical and scale inefficiencies in data envelopment analysis［J］. Manage Sci, 1984, 30(9): 1078-1092.

中国近年不同地区医药高科技产业研发效率分析

Research and development efficiency of pharmaceutical high-tech industry in different regions of China in recent years

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价